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Abstract
Background: We investigated the differences between the preferential primary therapy conceived by the primary
doctors and the primary therapy actually conducted for prostate cancer patients in Nara, Japan.
Methods: The distribution of primary therapy and clinical characteristics of 2303 prostate cancer patients -
diagnosed between 2004 and 2006 at Nara Medical University and its 23 affiliated hospitals - were assessed.
Moreover, the preferential primary therapy for the patients at each clinical stage (cT1-T3bN0M0) conceived by the
primary doctors was investigated and compared to the actual therapy.
Results: Of all patients, 51% received primary androgen deprivation therapy (PADT), 30% underwent radical
prostatectomy (RP), and 14% received radiation therapy (RT). The preferential primary therapy for cT1-2N0M0 was
RP (92%) while 38% of the patients actually received PADT (RP: 40%). For cT3aN0M0, the preferential primary
therapy was both RP and external beam radiation therapy (EBRT) while 58% of the patients actually received PADT
(RP: 16%, EBRT: 24%). For cT3bN0M0, the most preferential primary therapy was EBRT (46%) while 67% of the
patients actually received PADT (EBRT: 21%). This trend was more notable in the affiliated hospitals than in the
University hospital. The hospitals with lower volume of RP per year significantly conducted PADT compared with
those with higher volume of RP.
Conclusions: PADT was commonly used to treat localized prostate cancer as well as locally advanced prostate
cancer in Japan. There was a definite discrepancy between the preferential primary therapy conceived by the
primary doctors and the actual therapy provided to the patients.
Background
The distribution of the primary therapies for prostate
cancer is different between USA and Japan. Specifically,
more patients receive definitive therapies in USA than
in Japan. The CaPSURE data from USA indicated that
44% of patients underwent radical prostatectomy (RP),
23% received definitive radiotherapy (external beam
radiation therapy: EBRT, and brachytherapy: BT), and
20% received primary androgen deprivation therapy
(PADT) [1]. On the other hand, our data from Nara
Uro-Oncological Research Group (NUORG) showed
that the corresponding figures were 30%, 14%, and 51%,
respectively [2]. The differences are outstanding, parti-
cularly in the low-risk groupw i t ho r g a n - c o n f i n e ds t a g e
and Gleason score of <7 and PSA value of <10 ng/mL.
Analysis of the CaPSURE data between 2004 and 2006
[3] revealed that 60% of the low-risk patients received
RP and 7% received PADT. In contrast, 43% and 27% of
our low-risk patients received RP and PADT, respec-
tively [2]. The higher rate of hormonal therapy as the
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patients is remarkable and unique when compared with
American and European counterparts.
The contemporary trend of selecting the primary ther-
apy for prostate cancer varies among countries and
races according to the different socioeconomic situa-
tions. Reportedly the African American and low-income
patients are very apt to undergo RP and receive radio-
therapy of the relatively low medical cost [4,5]. The
elderly (over 75 years) and the patients with high aca-
demic background showed negative correlation with the
primary hormonal therapy and positive correlation with
the primary radiotherapy [6]. Ethnicity closely correlated
with the rate of choosing curative therapies [7]. The
African Americans were more likely to receive radio-
therapy as compared with RP, while Latinos were less
likely to receive radiotherapy as compared with RP.
Taken together, several socioeconomic factors (e.g., age,
ethnicity, educational level, and medical insurance sys-
tem) are very likely to influence the choice of primary
therapy for prostate cancer.
In this study, we investigated the trends of the most
preferential primary therapy conceived by urologists and
the primary therapy actually provided for patients with
localized prostate cancer in our NUORG institutions.
We then evaluated the differences in the primary treat-
ment choice between the university hospital and its
affiliates.
Methods
A total of 2371 patients diagnosed with prostate cancer
at Nara Medical University (NMU) hospital and its 23
affiliated hospitals between January 2004 and December
2006 were surveyed in this study. Due to incomplete
information at diagnosis, 68 patients were excluded
from this study. In total, 2303 patients were evaluated
for the clinical TNM classification of 2002 UICC, Glea-
son score of biopsy specimen, PSA value measured at
initial diagnosis, and actual primary therapy.
We asked 24 instructive urologists certificated by the
Japanese Urological Association (JUA) in all 24 hospitals
about the primary therapy for localized prostate cancer
in each stage (namely, cT1-2N0M0, cT3aN0M0 and
cT3bN0M0) using a self-developed questionnaire. The
questionnaire included questions about the most prefer-
ential primary therapy which they conceived if a given
patient had no concomitant diseases. As a treatment
option, PADT, RP, EBRT, BT (high-dose-rate and low-
dose rate) and watchful waiting (WW) were included in
this self-developed questionnaire. These modalities are
covered by public health insurance system in Japan. On
the other hand, cryosurgery and High Intensity Focused
Ultrasound are not covered by public health insurance
system, and therefore, these treatment options were not
included in this questionnaire. The distribution of the
most preferential primary therapy for localized and
locally advanced prostate cancer conceived by the urolo-
gists was compared to the chosen and performed pri-
mary therapy. Furthermore, we compared the real status
of primary therapy between the university hospital and
its affiliated hospitals.
To elucidate the correlation between the number of
RP per year and the proportion of PADT, we divided all
hospitals by 3 groups (Group 1, RP: 10 cases or less per
year; Group 2, 11-30 cases per year; and Group 3,
greater than 30 cases per year). The distribution of pri-
mary therapy among these 3 groups was examined, and
Spearman’s rank correlation test was used to examine
the significance of correlation between the number of
RP per year and the distribution of PADT at each
group.
To analyze the differences in categorical parameters,
the chi-square test was employed. Mann-Whitney U test
was used to evaluate the differences in continuous vari-
ables. All statistical analyses were performed using
PASW Statistics 17.0 (SPSS Inc., Chicago, IL, USA). All
p values less than 0.05 were considered as statistically
significant.
The institutional reviewer board approved this retro-
spective study. Obtaining informed consent from the
patients was exempted in the respect of the aim and
methods of this study.
Results
Primary therapy
The demographic characteristics of all 2303 patients are
shown in Table 1. The mean values of the patients’ age
and PSA value at diagnosis were 71.8 (median: 72.0)
years and 137.5 (median: 12.2) ng/mL, respectively. The
median age and PSA value at diagnosis in the affiliated
hospitals were significantly higher than those in the uni-
versity hospital (age: 73.0 vs. 71.0 years, p <0 . 0 0 1 ;P S A :
13.1 vs. 9.6 ng/mL, p < 0.001, respectively). Of all 2303
patients, 2117 (91.9%) showed no regional nodal metas-
tasis, 142 (6.2%) had regional nodal metastasis, and 44
were not informative about the nodal status. Further-
more, 1972 (86.6%) showed no distant metastasis, 84
(12.4%) had distant metastasis (11 with M1a, 257 with
M1b, and 16 with M1c), and 47 were not informative.
The patients who were treated at the university hospital
were younger with lower PSA level, lower Gleason
score, and lower clinical T stage (p < 0.001).
Among the 2303 patients, 51% were treated with
PADT, 30% underwent RP, 14% received radiation ther-
apy (RT), and 2% chose WW as the primary therapy.
The proportion of PADT in the affiliated hospitals was
significantly higher than that in the university hospital
(57% vs. 24%). The proportion of RP was comparable
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tals (29% vs. 31%). The proportion of EBRT in the uni-
versity hospital was significantly higher than that in the
affiliated hospitals (44% vs. 7%) (p < 0.001).
Preferential primary therapy
Of the 2303 patients, 1609 were in cT1-2N0M0, 211
were in cT3aN0M0, and 94 were in cT3bN0M0. Regard-
ing the preferential primary therapy of cT1-2N0M0, RP
was highly recommended by urologists (92%). In con-
trast, no urologist raised PADT as the preferential pri-
mary therapy (Figure 1A). With regard to the actual
therapies, however, only 40% of patients underwent RP
and 38% received PADT (Figure 1B). The number of
patients who received PADT in the affiliated hospitals
was higher when compared to that in the university hos-
pital (44% vs. 14%, p = 0.001) (Figure 1C, D).
Concerning the breakdown of the preferential primary
therapy for cT3aN0M0, the proportions of RP and
EBRT were equal (42% each) (Figure 2A). Interestingly,
breakdown of the actual therapies revealed that 58% of
the patients received PADT (Figure 2B). The proportion
of PADT in the affiliated hospitals was 67%, being sig-
nificantly higher than in the university hospital (33%, <
0.001) (Figure 2C, D). Conversely, the proportion of
EBRT in the university hospital was significantly higher
than in the affiliated hospitals (42% vs. 18%, p < 0.001).
Regarding the preferential primary therapy for
cT3bN0M0, RP and PADT were adopted by 38% and
46% of urologists, respectively (Figure 3A). In contrast,
the proportions of the actual therapies were 67% for
PADT, 21% for EBRT, and 9% for RP (Figure 3B). In the
affiliated hospitals, 74% of the patients received PADT
whereas 43% received PADT in the university hospital (p
< 0.001) (Figure 3C, D). The proportion of EBRT in the
university hospital was significantly higher than that in
the affiliated hospitals (57% vs. 11%, p < 0.001).
The correlation between the number of RP and the
distribution of PADT
Of the 2303 patients, 1914 were in cT1-3N0M0. Of all
hospitals, 15 hospitals were defined as Group 1 (the
number of RP per year: 10 cases or less), 7 hospitals as
G r o u p2( t h en u m b e ro fR Pp e ry e a r :1 1t o3 0c a s e s ) ,
and 2 hospitals as Group 3 (the number of RP per year:
greater than 30 cases). The University hospital is in
Group 3, and RT is available in both hospitals in Group
3. The distribution of primary therapy was significantly
different among these 3 groups (Figure 4, p <0 . 0 0 1 ) .
The group with higher percentage of RP showed signifi-
cantly lower percentage of PADT compared with the
group with lower percentage of RP. Moreover, there was
a significant inverse correlation between the number of
RP and the distribution of PADT (r = -0.291, p < 0.001).
Table 1 Demographic characteristics of 2303 patients
Overall University hospital Affiliated hospitals
n = 2303 (%) n = 420 (%) n = 1883 (%) P value
Age (years)
younger than 60 154 (6.7) 52 (12.4) 102 (5.4)
60-69 684 (29.7) 130 (31.0) 554 (29.4)
70-79 1117 (48.5) 199 (47.3) 918 (48.8)
80 or older 348 (15.1) 39 (9.3) 309 (16.4) < 0.001
PSA at diagnosis
10.0 or less 963 (41.8) 225 (53.5) 738 (39.2)
10.1-20 554 (24.1) 98 (23.3) 456 (24.2)
greater than 20 786 (34.1) 97 (23.1) 689 (36.6) < 0.001
Gleason score
2-6 906 (39.3) 146 (34.8) 760 (40.3)
7 722 (31.4) 175 (41.6) 547 (29.0)
8-10 675 (29.3) 99 (23.6) 576 (30.6) < 0.001
Clinical T stage
T1 766 (33.3) 183 (43.6) 583 (31.0)
T2 933 (40.5) 134 (31.9) 799 (42.4)
T3 489 (21.2) 95 (22.6) 394 (20.9)
T4 115 (5.0) 8 (1.9) 107 (5.7) < 0.001
Chi-square test.
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Previously we reported that our series of patients (trea-
ted between 2004 and 2006) received PADT more fre-
quently than in USA [2]. Relatively more patients chose
PADT as the primary therapy not only for locally
advanced prostate cancer but also for localized prostate
cancer in Japan [8-11]. This nation-wide trend in Japan
is apparently dissimilar from that in the Western coun-
tries [1-3]. According to the JUA report, for example,
57% of the registered patients received PADT, 28%
underwent RP with or without neoadjuvant or adjuvant
therapy, and 8% received RT with or without neoadju-
vant therapy in 2000 [9]. In comparison between our
report and the 2000 JUA report, the proportion of RT
in our report was significantly higher than that of JUA
report (14% vs. 8%), while the proportion of PADT was
significantly lower than that of the JUA report (51% vs.
57%) (p < 0.001, chi-square test; data not shown). Since
low-dose rate brachytherapy was legally approved by the
government in 2003, RT overall including high-quality
EBRT like intensity modulated radiation therapy and
three-dimensional radiation therapy has been increasing
no less than brachytherapy in Japan year after year. The
proportion of RT is likely to hereafter increase alterna-
tively to PADT in Japan.
Several specific reasons for this trend in Japan are pro-
posed. First, all patients are covered completely by the
total public health insurance system in Japan. All
patients including even no-income people can receive
any therapy they like under the public insurance cover-
age. In principle, the patients continue PADT until they
show androgen independency. The therapy cost
increases until cessation of PADT. Secondly, the Japa-
nese patients tolerate well receiving hormonal therapy
without severe side effects. Akaza et al reported that
there was no significant difference in the overall survival
between the patients with localized prostate cancer trea-
ted with PADT and the age-matched men in the general
population [12]. Akaza et al also reported that the inci-
dence of cardiovascular events in patients treated with
PADT
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Figure 1 The distribution of the preferential primary therapy (A), the actual primary therapy for all 1609 patients (B), in NMU hospital
(C), and in the affiliated hospitals (D) for the patients with cT1-2N0M0 (Chi-square test; = 0.001, NMU hospital vs. affiliated hospitals).
NMU; Nara Medical University, RP; radical prostatectomy, PADT; primary androgen deprivation therapy, HDR; high dose rate brachytherapy, BT;
brachytherapy, EBRT; external beam radiation therapy, WW; watchful waiting.
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general Japanese population [13]. On the other hand,
the newly diagnosed prostate cancer patients who
received PADT for at least one year showed a 20%
higher risk of serious cardiovascular morbidity as com-
pared with similar men who did not receive PADT in
the SEER database [14]. Although there is no direct
comparison of the cardiovascular morbidity in the
patients who receive PADT between Japanese and Wes-
tern men, serious cardiovascular events are apparently
not frequently experienced in the Japanese patients who
received hormonal therapy. Thirdly, the majority of the
Japanese patients interestingly do not reject receiving
hormonal therapy because of the low priority of preser-
ving erectile function at the time of treatment selection.
Additionally, most recently robotic surgery was intro-
duced in Japan and robotic-assisted radical prostatect-
omy is currently available in the several legally
authorized hospitals. Since the number of robotic-
assisted radical prostatectomy cases has belatedly
increased in those limited institutes, the near-future
prevalence of this surgical modality will not a little influ-
ence selection of less invasive primary therapy for early
prostate cancer.
In our data, most primary urologists conceived that
RP is the preferential primary therapy for cT1-2N0M0
prostate cancer. Nevertheless, the proportion of patients
who actually chose and received RP was 40%, but those
who received PADT accounted for nearly 40%. Of
course, some patients could not receive the definitive
therapy due to several limitations such as co-morbidity,
o l da g ea n ds oo n .N o n e t h e l e s s ,t h ep r o p o r t i o no f
PADT for this clinical stage was higher in Japan than in
the Western countries [3]. Since only 3 affiliated hospi-
tals could provide EBRT, and BT is currently available
only in the university hospital, this status strongly affects
the different proportions of EBRT and BT between the
university hospital and its affiliates. Indeed, the present
high proportion of BT and EBRT (over 45%) was attrib-
uted to the recent increase in patients who were
referred to the university hospital with their own choice
for RT.
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Figure 2 The distribution of the preferential primary therapy (A), the performed primary therapy for all 211 patients (B), in NMU
hospital (C), and in the affiliated hospitals (D) for the patients with cT3aN0M0 (Chi-square test; < 0.001, NMU hospital vs. affiliated
hospitals). NMU; Nara Medical University, RP; radical prostatectomy, PADT; primary androgen deprivation therapy, HDR; high dose rate
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preferential primary therapy for cT3aN0M0 prostate
cancer. Interestingly, over 40% of urologists considered
RP as the preferential therapy for cT3a prostate cancer.
However, PADT was the highest with the actual rate of
58%. In the university hospital, 42% of the patients
received EBRT and 33% underwent PADT. On the
other hand, two-thirds of patients received PADT in the
affiliated hospitals. Although 46% of urologists selected
EBRT for cT3bN0M0, an unexpectedly high rate (38%)
of urologists considered that RP was still the preferential
primary therapy. However, two-thirds of the patients
actually received PADT while 21% and 9% received
EBRT and RP, respectively. In the university hospital, no
patients with cT3b prostate cancer underwent RP.
Overall, the proportion of PADT in our data was as
high as that of the JUA report [9]. Relatively a large
population of the urologists is likely to choose RP as the
preferential primary therapy for cT3 stage. However, the
most common primary therapies were RT in the
university hospital and PADT in its affiliated hospitals.
A small number of the urologists actually still performed
RP even for higher stage prostate cancer. Our specula-
tion is that this trend in the affiliated hospitals may be
due to retrospection of unpleasant experiences with old-
fashioned RT and unawareness of the recent technologi-
cal advances in RT during their long-term career as
urologists. The educational and institutional prevalence
of RT, as an alternative to PADT, seems to be necessary
for both urologists and patients with advanced prostate
cancer in Japan.
Interestingly, the present study showed that the hospi-
tals with lower volume of RP significantly conducted
PADT compared with those with higher volume of RP
in patients with cT1-3N0M0 (Figure 4). RT was avail-
able in 1 hospital in Group 2 and all hospitals in Group
3. The proportion of PADT was significantly higher in
the hospitals where RT was not available in own hospi-
tal than those where RT was available. Recently, Barocas
et al reviewed the available literature on the impact of
EBRT
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g
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Figure 3 The distribution of the preferential primary therapy (A), the performed primary therapy for all 94 patients (B), in NMU
hospital (C), and in the affiliated hospitals (D) for patients with cT3bN0M0 (Chi-square test; < 0.001, NMU hospital vs. affiliated
hospitals). NMU; Nara Medical University, RP; radical prostatectomy, PADT; primary androgen deprivation th1erapy, HDR; high dose rate
brachytherapy, EBRT; external beam radiation therapy, WW; watchful waiting.
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RP. They reported a substantial advantage (e.g. length of
hospital stay, peri-operative complications, peri-opera-
tive mortality, treatment failure and so on) for patients
treated in high volume hospitals and by high volume
surgeons [15]. It is conceivable that the choice of pri-
mary therapy by patients and doctors would depend on
the volume of RP and the variety of treatment modal-
ities. Unfortunately, the correlation between high
volume hospital and the outcomes in the present study
cohort has not been evaluated. A further investigation
with substantial follow-up period makes it possible to
elucidate this issue.
There were several limitations of this study. First, we
used a self-developed questionnaire to determine the
preferential therapy by doctors at each clinical stage.
This questionnaire has not been externally validated.
Second, we did not conduct the survey in patients strati-
fied risk classification. It is more preferable to survey the
preferential primary therapy at the moment. Third, this
study was lacking in the aspect of co-morbidity of
patients. Fourth, it would be more informative if a
patient-directed questionnaire were adopted.
Conclusions
There are explicit differences in choosing the primary
therapy for prostate cancer between the university hos-
pital and its affiliated hospitals, and PADT was com-
monly provided to our patients with localized prostate
cancer as well as those with locally advanced prostate
cancer in the affiliated hospitals. This trend was mainly
caused by discrepancy between the preferential primary
therapies conceived by urologists and the actual treat-
ment after thorough considerations of the patients’
backgrounds and available therapeutic modalities.
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